Geoffrey Maltzahn

Geoffrey von Maltzahn joined Flagship Pioneering in 2009 and serves as general partner.
He is an inventor, entrepreneur, CEO, and the co-founder of multiple groundbreaking companies that integrate biology and data science to transform human health and sustainability.
Through his role in Flagship Labs, the company’s innovation foundry, Geoffrey has created companies that include Tessera Therapeutics, Generate Biomedicines, Indigo Agriculture, Sana Biotechnology (NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB), and Axcella Health (NASDAQ: AXLA).
Geoffrey currently serves as board chair of Tessera Therapeutics, chief innovation officer and board director of Indigo Agriculture, board director of Generate Biomedicines, and as CEO of multiple new stealth therapeutics and sustainability companies.
Geoffrey has served as founding chief executive officer of several Flagship companies including: Tessera Therapeutics, where he led the development of its pioneering Gene Writing™ technology; Cobalt Biomedicine, which he led from inception to merger with Sana Biotechnology; and Indigo, where he led the development of the company’s plant microbiome platform and the discovery of the company’s first commercial products: Indigo Cotton, Indigo Wheat, Indigo Corn, and Indigo Soy, which are now used on millions of acres.
Previously, Geoffrey was the chief technology officer of Seres Therapeutics, where he led the discovery of SER-109, the first microbiome therapeutic to report positive Phase 3 data, and built out the company’s discovery platform.
Geoffrey was awarded a PhD in biomedical engineering and medical physics from MIT under the mentorship of Sangeeta N.
Bhatia, MD, PhD; an MS in bioengineering from the University of California, San Diego; and an SB in chemical engineering from MIT.